Transforming growth factor-beta receptor and related TGF-beta superfamily receptors (TGFBR)

The Transforming growth factor-beta (TGF-beta) receptor superfamily consists of a diverse group of transmembrane serine/threonine kinases that mediate the effects of a wide variety of ligands, including TGF-betas, bone morphogenetic proteins (BMPs), activins, and growth differentiation factors (GDFs) [PMID: 28213285]. These receptors typically operate as heteromeric complexes consisting of Type I and Type II subunits; ligand binding induces the Type II receptor to phosphorylate the Type I receptor, which then activates downstream SMAD-dependent and SMAD-independent signaling pathways [UniProt: P36897, P37173]. This signaling is fundamental to cellular processes such as proliferation, differentiation, apoptosis, and tissue homeostasis [PMID: 15181153]. In disease, dysregulated TGF-beta signaling is a key driver of cancer progression—promoting metastasis, epithelial-mesenchymal transition (EMT), and immune evasion—as well as tissue fibrosis in organs like the lungs and kidneys [PMID: 30442715]. Therapeutic approaches targeting this superfamily include small-molecule kinase inhibitors (e.g., targeting ALK5), ligand-sequestering monoclonal antibodies, and recombinant decoy receptors known as ligand traps [PMID: 32824544]. Despite their therapeutic potential, targeting these receptors is associated with significant safety concerns, including cardiotoxicity and the development of benign or malignant skin lesions, due to the pleiotropic nature of the pathway [PMID: 22431504, 24501019].

Other names

TGF-beta receptorTGF-beta superfamily receptorSerine/threonine-protein kinase receptorActivin receptorBone morphogenetic protein receptorBMP receptorALK receptorTGFBRACVRBMPR

Inhibition of the intracellular serine/threonine kinase activity of Type I receptors, sequestration of ligands by monoclonal antibodies or decoy receptor fusion proteins (ligand traps), and bifunctional blockade of receptor signaling and immune checkpoints.